Lab Manager | Run Your Lab Like a Business

Fujirebio Diagnostics Files 510(K) with FDA for Lumipulse® G β-Amyloid Ratio (1-42/1-40) in Vitro Diagnostic Test

When cleared, Fujirebio’s FDA-designated breakthrough device is expected to be among the first commercially available in vitro diagnostics for patients being evaluated for Alzheimer’s disease in the US

Fujirebio Diagnostics Files 510(K) with FDA for Lumipulse® G ?-Amyloid Ratio (1-42/1-40) in Vitro Diagnostic Test

The test was granted Breakthrough Device Designation by the FDA in February 2019 and is expected to be among the first commercially available in vitro diagnostic tests in the US to help in the assessment of Alzheimer’s disease.

by
Fujirebio Diagnostics

Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pioneered and introduced the CA125...

ViewFull Profile.
Learn about ourEditorial Policies.
Register for free to listen to this article
Listen with Speechify
0:00
5:00

MALVERN, PA — December 2, 2020 — Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that it has filed its Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test with the US Food and Drug Administration (FDA) for 510(k) premarket clearance. The test was granted Breakthrough Device Designation by the FDA in February 2019 and is expected to be among the first commercially available in vitro diagnostic tests in the US to help in the assessment of Alzheimer’s disease. The test is analyzed using Fujirebio’s fully automated Lumipulse G1200 instrument system.

Alzheimer’s disease is a devastating condition, characterized by amyloid plaques in the brain, which afflicts more than 5 million Americans and is a leading cause of disability and death. Current tools available to evaluate amyloid pathology such as amyloid PET imaging can be expensive, time consuming, and difficult to access. As a result, many patients are not diagnosed until their disease is well advanced, with few available treatment options.

Get training in Lab Crisis Preparation and earn CEUs.One of over 25 IACET-accredited courses in the Academy.
Lab Crisis Preparation Course

The Lumipulse G β-Amyloid Ratio (1-42/1-40) combines the concentrations of Lumipulse G β-Amyloid 1-42 and Lumipulse G β-Amyloid 1-40 found in human cerebral spinal fluid (CSF) into a numerical ratio of β-Amyloid1-42/ β-Amyloid1-40. The ratio is a semiquantitative in vitro diagnostic test intended to be used in adult patients, aged 50 years and over, presenting with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.   

“The lack of effective and accessible clinical tools for patients who could be on the pathway to develop Alzheimer’s disease contributes to its late diagnosis and inadequate treatment,” says Monte Wiltse, president and CEO at Fujirebio Diagnostics, Inc. “We designed our Lumipulse G β-Amyloid Ratio test to help physicians triage their patient much sooner when effective interventions are more feasible using these well- researched β-amyloid biomarkers. Accurate and earlier intervention will also facilitate the development of new drug therapies, which are urgently needed as the prevalence of Alzheimer’s disease increases with a rapidly aging population globally.”

The Lumipulse G β-Amyloid and Tau tests are already CE-marked for use in the European Union.

Fujirebio Diagnostics

Fujirebio Diagnostics